mRNAs and miRNAs profiling of Mesenchymal Stem Cells derived from amniotic fluid and skin

Mesenchymal Stem Cells (MSCs) may be isolated from different adult sources and even if the minimal criteria for defining MSCs have been reported, the scientific question about the potential distinctions among MSCs derived from different sources is still opened. In particular, it is debated if MSCs of different origin have the same grade of stemness or if the source affects their undifferentiated status. Here we report not only the isolation and the traditional characterization of MSCs derived from amniotic fluid (AF-MSCs) [1] and skin (S-MSCs) [2], but also a molecular characterization based on mRNAs and miRNAs profiling. Our results show that even if both AF- and S-MSCs are regulated by the same pathways (such as Wnt, MAPK and TGF-β), there is a fine and different control of them as suggested by altered levels of expression of some member of these pathways. In conclusion, it will be necessary to improve the knowledge about the role of each dysregulated miRs/gene because, actually, these differences may strengthen the question about the importance of tissue origin. This work was supported by grant FIRB-RBAP10MLK7_003 from Ministero dell’Istruzione, dell’Università e della Ricerca, Rome, Ital

The inflamed microenvironment: role on MSCs immunobiology and cancer

Inflammation and cancer are an inseparable binomial. The majority of cancers are triggered by somatic mutations and environmental factors with a common element: inflammation. Inflammation creates a microenvironment in which neoplastic cells can profit from the trophic factors secreted by inflammatory cells, useful to interfere with the anti-tumor response. Among the others, mesenchymal stem cells (MSCs) participate to microenvironment creation by a strong paracrine effect. The linkage between MSCs and inflammation is bidirectional: the inflamed microenvironment affects the complex MSCs immunobiology, but also MSCs can sustain inflammation. Here, we tried to clarify the influence of inflammation on the immunobiology of MSCs and deepen the paracrine effect of MSCs on tumor growth. MSCs were isolated from periprosthetic capsule caused by breast implant, affected by inflammation (I-MSCs). The contralateral part of the same patient, not inflamed, was used as control (C-MSCs). A panel of selected cytokines were analyzed by Real-Time PCR and ELISA. The cytokines expression was different in I-MSCs compared to C-MSCs, revealing that inflammation affects MSCs immunobiology. Then, C- and I-MSCs were indirectly co-cultured with MCF7 cells from breast adenocarcinoma. New analyses on proliferation rate and cytokines expression were performed. C- and I-MSCs gave almost the same results. The over-secretion of all the cytokines referred to the Th1 pathway and the decrease of those belonging to the Th2 pathway revealed the absence of a switch from Th1 to Th2 important to induce a chronic inflammation. The levels of TGF-β and G-CSF linked to the skill to damage the antigen-presenting cell function were decreased. In conclusion, even if MCF-7 proliferation increased after co-culture with I-MSCs, MSCs-derived paracrine effect does not sustain breast adenocarcinoma. These results absolve the breast implants from the insult to enhance adenocarcinoma onset

Isolation and characterization of Mesenchymal Stem Cells from pituitary tumours

In the past few years the introduction of the cancer stem cells (CSCs) notion opened new perspectives for the diagnosis and cure of solid tumors. According to this theory, CSCs originate from mutated stem cells, maintaining the self-renewal and differentiative abilities. Therefore, the development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients. Actually, no informations are available about stem cells and cancer stem cells on pituitary tumours. This work depicts some essential features of stem cells isolated from pituitary adenomas. Six tumour biopsies (3: GH-secreting; 3: non secreting) were collected and cultured with a specific culture medium. Cell growth and morphology were monitored and cells were subjected to analyses for stemness determination (immunophenotype, gene expression and differentiative potential) [1, 2] and GH secretion. Cells showed a stem-like immunophenotype, the expression of Oct-4, Sox-2, Nanog and Klf-4 and the ability to differentiate towards osteogenic, chondrogenic and adipogenic lineages. The hormone secretion ended after two weeks culturing. Even if further studies are needed for the fully comprehension of the specific nature of these cells and on their role on tumour onset and maintenance, this study opens to the possibility of isolation of stem cells from pituitary tumour, allowing a molecular targeting of it. This work was supported by grant FIRB-RBAP10MLK7_003 from Ministero dell’Istruzione, dell’Università e della Ricerca, Rome, Ital

The role of the mesenchymal stem cells on breast cancer: friends or foes?

Mesenchymal stem cells (MSCs) have been the subject of an increased interest. Because of their ability to give rise to bone, cartilage, fat and muscle, their role in regenerative medicine has been extensively studied and the fact that they can be recruited at sites of inflammation and tissue repair has prompted their potential use as tissue regenerative cells. Contextually there has been a growing interest in the role of MSCs in cancer progression. The nature of the relationship between MSCs and tumor cells appears dual, with effects pro- as well as anti-tumorigenic. This paradox depends on the source and the degree of differentiation of MSCs and the tumor model used. Moreover, with the large range of cytokines and growth factors they produce, MSCs exert regulatory function on apoptosis, angiogenesis and an immunomodulatory role. Here we evaluate the interaction between MSCs derived from the periprosthetic capsule of mastectomyzed women and the breast cancer cell line MCF-7. Capsular tissue around breast implants is a normal inflammatory reaction versus a foreign body and it is rich of MSCs. To asses how MSCs interact with tumor cells, MCF-7 cells were incubated with medium previously conditioned by MSCs or directly co-coltured with MSCs; subsequently, we evaluated the proliferation and the expression of genes implicated in different pathways (angiogenesis, proliferation, anti-apoptosis, EMT transition). Our results showed that MCF-7 cells cultured together MSCs or using their conditioned medium have a more elevated proliferation rate but tumour cells seem less aggressive, like attested by a reduction of the expression of selected genes. The understanding of the mechanisms that control the interaction between MSCs and tumor cells is still at an early stage but recent literature confirm that MSCs and their progeny are not innocent bystanders in the tumor microenvironment. The study of these interactions is a critical area of future investigation that is needed to better define their role in cancer progression and their potential as therapeutic agents or targets

From nucleus pulposus mesenchymal stem cells towards neural differentiation: an interesting prospect

Regenerative medicine arouses great interest for the treatment of many neurological diseases. Since nucleus pulposus of the invertebral discs is a postembryonic vestige of the notochord, it has been hypothesized that mesenchymal stem cells (MSCs) isolated from nucleus pulposus (NP-MSCs) can more easily differentiate into neurons. In this study, MSCs from nucleus pulposus were successfully isolated and characterized. Then, neural differentiation was induced by using a medium consisted of DMEM/F12 supplemented with B27 and the growth factors FGF and EGF for 10 days. Immunocytochemistry, molecular studies, SEM and TEM microscopy analyses were performed. NP-MSCs exhibited the typical features of MSCs, revealing spindle-shape morphology, specific immunophenotype attributable to MSCs and the ability to differentiate in osteogenic and chondrogenic lineages. After neurodifferentiation induction, compared to NP-MSCs in only DMEM/F12, proliferation rate decreased and cells changed morphology acquiring an increased number of the so-called neural-like extensions. Neural progenitor marker NESTIN and mature neuronal marker ENOLASE-2 were up-regulated, while GFAP was not detected. Moreover, cells after differentiation were small rounded and fusiform, with tendency to organize in clumps; they had elongated extrusions containing oriented cytoskeletal elements, classifiable as microtubules and intermediate filaments, as visualized by SEM and TEM microscopy. Dense vesicles similar to lipid droplet were also observed. NP-MSCs in differentiation medium were able to form neurospheres. In conclusion, even if more analysis have to be done and the way to treat neurodegenerative disease with regenerative medicine is still long, NP-MSCs represent a promising resource

Crosstalk between Mesenchymal Stem Cells and tumor cells: the role of inflammation

Mesenhymal Stem Cells (MSCs) are self-renewal multipotent cells that can be isolated from different adult tissues. There is a growing interest in the role exerted by MSCs in cancer progression. MSCs exhibit a marked tropism for tumors and par- ticipate to the creation of the stroma and related inflammation, which has a critical role in carcinogenesis, progression and metastasis. Nevertheless, while many studies showed that MSCs promote tumor progression and metastasis, others reported that MSCs suppress tumor growth. These contradictory results may be due to the origin of the MSCs, their degree of differentiation, the tumor model and other factors that are not yet elucidated. Aim of this work was to establish the role of the paracrine effect exerted by MSCs isolated from inflamed (I-MSCs) and control (C-MSCs) tis- sues towards human MCF7 and KI-JK cell lines, respectively derived from a breast cancer and an anaplastic large T cell lymphoma (ALCL). After stemness characteriza- tion, MSCs were indirectly co-cultured with MCF7 or KI-JK for 7 days; subsequently the proliferation rate and the expression of specific genes were tested. Genes were selected according to their role in inflammation and cancer previously reported in literature and explicate their action by different mechanisms: chemokines with pro- (CXCL2, CXCL9) or anti-angiogenic effect (CXCL10); chemokines (CCL2, CXCL12, CXCL5) for the recruitment of myeloid-derived suppressor cells (MDSCs); interleu- kins distinctive for chronic (IL2, IL4) and acute (IL8, IL16) inflammation; cytokines belonging to the Th2 subset (CCL22, IL13, IL22, CCL17, CCL18); cytokines (IL6, IL10 and TGFβ1) involved in the manipulation of the antigen-presenting cells function. Our data confirm a role of MSCs in cancer; an increase of pro-angiogenic chemokines as well as of interleukin related to acute phase of inflammation, a general switch of the T cell response from the Th1 cell subset to the Th2 subset and the induction of MDSCs were observed. Surprisingly, these effects have been mainly found in both cancer cell lines after co-culture with C-MSCs; it may mean that I-MSCs, suffering of chronic inflammation, are less responsive than C-MSCs to new stress/stimuli. Fur- ther experiments will be necessary to better address the role of MSCs and inflamma- tion on cancer progression; nevertheless, this study highlight as MSCs are not simply guardian but active actors in cancer fate

MSCs and inflammation: not only a guardian role

  The literature on the relation between mesenchymal stem cells (MSCs) and inflammation is continuing to expand at a rapid rate with over 600 entries in PubMed under “MSCs and inflammation” starting from 2002. Inflammation is an essential part of the malignant microenvironment. Chemokines, leukocyte infiltration and cytokines are crucial elements, which contribute to cancer-related inflammation. Attracted by chemokines, MSCs are recruited at injury sites. After exposure to inflammatory factors in the local microenvironment, MSCs secrete several cytokines and vascular endothelial growth factor, which promote immunosuppression, angiogenesis and tumor growth. Here we compare by RT-PCR the expression of selected genes, related to inflammation, on MSCs derived from control (C-MSCs) and inflamed tissues (I-MSCs). First of all, an immunohistochemistry using anti-CD43 antibody was performed to better test the status of inflammation at the moment of tissues’ collection. CD43 is known as marker of inflammation, since it is expressed by most T cells, activated B cells, basophils, macrophages, monocytes and NK cells. Its expression was absent in “control” tissues, while it was strong in the “inflamed”. Subsequently, RNA was extracted, retro-transcribed and used for quantitative PCR. The genes were selected according to their role in inflammation: IL6 and IL8 (known as pro-inflammatory interleukins), TNFα (involved in systemic inflammation), CXCL2 (secreted by monocytes and macrophages and is chemotactic for polymorphonuclear leukocytes), CCL20 (strongly chemotactic for lymphocytes, its expression is induced by inflammatory cytokines), IFNγ (an important activator of macrophages) and TGFβ1 (promoting immunosuppression). Quantification of mRNA expression was calculated with the 2−ΔΔCt method, where ΔCt = Ct (gene of interest) − Ct (control gene) and Δ(ΔCt) = ΔCt (I-MSCs) − ΔCt (C-MSCs). The results revealed that the expression of all tested genes was higher in MSCs derived from inflamed tissues than in MSCs from control tissues (expressed as 1). This study underlines how MSCs are not inert guardians on inflammation, but as they play an active role

Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging.

none15noopenF Olivieri; L Spazzafumo; G Santini; R Lazzarini; MC Albertini; MR Rippo; R Galeazzi; AM Abbatecola; F Marcheselli; D Monti; R Ostan; E Cevenini; R Antonicelli; C Franceschi; AD Procopio.F., Olivieri; L., Spazzafumo; G., Santini; R., Lazzarini; Albertini, MARIA CRISTINA; Mr, Rippo; R., Galeazzi; Am, Abbatecola; F., Marcheselli; D., Monti; R., Ostan; E., Cevenini; R., Antonicelli; C., Franceschi; Ad, Procopi

Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions : a study on postmenopausal monozygotic twin pairs

MiRNAs are fine-tuning modifiers of skeletal muscle regulation, but knowledge of their hormonal control is lacking. We used a co-twin case-control study design, that is, monozygotic postmenopausal twin pairs discordant for estrogen-based hormone replacement therapy (HRT) to explore estrogen-dependent skeletal muscle regulation via miRNAs. MiRNA profiles were determined from vastus lateralis muscle of nine healthy 54-62-years-old monozygotic female twin pairs discordant for HRT (median 7 years). MCF-7 cells, human myoblast cultures and mouse muscle experiments were used to confirm estrogen's causal role on the expression of specific miRNAs, their target mRNAs and proteins and finally the activation of related signaling pathway. Of the 230 miRNAs expressed at detectable levels in muscle samples, qPCR confirmed significantly lower miR-182, miR-223 and miR-142-3p expressions in HRT using than in their nonusing co-twins. Insulin/IGF-1 signaling emerged one common pathway targeted by these miRNAs. IGF-1R and FOXO3A mRNA and protein were more abundantly expressed in muscle samples of HRT users than nonusers. In vitro assays confirmed effective targeting of miR-182 and miR-223 on IGF-1R and FOXO3A mRNA as well as a dose-dependent miR-182 and miR-223 down-regulations concomitantly with up-regulation of FOXO3A and IGF-1R expression. Novel finding is the postmenopausal HRT-reduced miRs-182, miR-223 and miR-142-3p expression in female skeletal muscle. The observed miRNA-mediated enhancement of the target genes' IGF-1R and FOXO3A expression as well as the activation of insulin/IGF-1 pathway signaling via phosphorylation of AKT and mTOR is an important mechanism for positive estrogen impact on skeletal muscle of postmenopausal women.Peer reviewe

Expression of Trop2 in bladder cancer is modulated by miR125b: in vivo and in vitro analyses

Human trophoblastic cell surface antigen 2 (Trop-2) is a 40-kDa transmembrane glycoprotein, first identified as a cell surface marker for human trophoblast cells (1). Elevated expression of Trop-2 has been shown in several types of epithelial cancers and correlated with tumour aggressive and poor prognosis (2-3). The first aim of this study was to evaluate the variation of the Trop-2 expression in normal urothelium and urothelial bladder cancer. The immunohistochemical results showed an increase of Trop-2 levels in bladder cancer tissues with the increase of the severity of the pathology. Recent data identified Trop-2 as a target for miR-125b suggesting a pos sible role of miR-125b in the modulation of Trop-2 protein expression (4). The second aim was to verify if Trop-2 could be a target for miR-125b in bladder cells and to evaluate the possible role of miR-125b in the modulation of Trop-2 protein expression in normal bladder as well as in urothelial bladder cancer. In vitro we showed a contribution of miR-125b in deregulation of Trop-2 protein expression in a bladder cell line and we found that the expression of miR-125b was inversely correlated with the expression of Trop-2 protein on a cohort of bladder cancer tissues. We concluded to investigate in a larger population the use of Trop-2 and/or miR-125b as potential diagnostic markers in urothelial bladder cancer